Clinical trial NCT00515203 - References

Idiopathic Thrombocytopenic Purpura — Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Citation(s)

•   Bussel J, Buchanan G, Nugent D, Gnarra D, Blanchette V, Nie K, Jun S
  A randomized, double-blind, placebo-controlled phase 1/2 study to determine the safety and efficacy of romiplostim in children with chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). Blood;2011;118:28-36
•   Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V
  Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9.

A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects With Chronic Immune (Idiopathic) Thrombocytopenic Purpura

Details for clinical trial NCT00515203